These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 28031409)
1. Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation. Xie X; He G; Siddik ZH Mol Cancer Res; 2017 Mar; 15(3):328-339. PubMed ID: 28031409 [TBL] [Abstract][Full Text] [Related]
2. Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Xie X; Lozano G; Siddik ZH Oncogene; 2016 Sep; 35(36):4798-806. PubMed ID: 26876197 [TBL] [Abstract][Full Text] [Related]
3. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells. Bhatt M; Ivan C; Xie X; Siddik ZH Oncotarget; 2017 Feb; 8(7):10905-10918. PubMed ID: 28038466 [TBL] [Abstract][Full Text] [Related]
4. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents. Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366 [TBL] [Abstract][Full Text] [Related]
5. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719 [TBL] [Abstract][Full Text] [Related]
6. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Siddik ZH; Mims B; Lozano G; Thai G Cancer Res; 1998 Feb; 58(4):698-703. PubMed ID: 9485023 [TBL] [Abstract][Full Text] [Related]
7. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Fraser M; Bai T; Tsang BK Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180 [TBL] [Abstract][Full Text] [Related]
8. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation. Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398 [TBL] [Abstract][Full Text] [Related]
9. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation. Sørensen BH; Nielsen D; Thorsteinsdottir UA; Hoffmann EK; Lambert IH Am J Physiol Cell Physiol; 2016 Jun; 310(11):C857-73. PubMed ID: 26984736 [TBL] [Abstract][Full Text] [Related]
10. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971 [TBL] [Abstract][Full Text] [Related]
11. Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance. Siddik ZH; Hagopian GS; Thai G; Tomisaki S; Toyomasu T; Khokhar AR J Inorg Biochem; 1999 Oct; 77(1-2):65-70. PubMed ID: 10626356 [TBL] [Abstract][Full Text] [Related]
12. Characterisation of the p53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines. Pestell KE; Medlow CJ; Titley JC; Kelland LR; Walton MI Int J Cancer; 1998 Sep; 77(6):913-8. PubMed ID: 9714063 [TBL] [Abstract][Full Text] [Related]
13. Prolonged wild-type p53 protein accumulation and cisplatin resistance. Yazlovitskaya EM; DeHaan RD; Persons DL Biochem Biophys Res Commun; 2001 May; 283(4):732-7. PubMed ID: 11350044 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of CCDC69 activates p14 Cui L; Zhou F; Chen C; Wang CC J Ovarian Res; 2019 Jan; 12(1):4. PubMed ID: 30651135 [TBL] [Abstract][Full Text] [Related]
15. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Pestell KE; Hobbs SM; Titley JC; Kelland LR; Walton MI Mol Pharmacol; 2000 Mar; 57(3):503-11. PubMed ID: 10692490 [TBL] [Abstract][Full Text] [Related]
16. Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation. Shono T; Tofilon PJ; Schaefer TS; Parikh D; Liu TJ; Lang FF Cancer Res; 2002 Feb; 62(4):1069-76. PubMed ID: 11861384 [TBL] [Abstract][Full Text] [Related]
17. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Yan X; Fraser M; Qiu Q; Tsang BK Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436 [TBL] [Abstract][Full Text] [Related]
18. The association between p53 protein phosphorylation at serine 15, serine 20 and sensitivity of cells isolated from patients with ovarian cancer and cell lines to chemotherapy in in vitro study. Kamińska I; Bar JK Pharmacol Rep; 2018 Jun; 70(3):570-576. PubMed ID: 29684847 [TBL] [Abstract][Full Text] [Related]
19. In vitro studies on the mechanisms of oxaliplatin resistance. Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458 [TBL] [Abstract][Full Text] [Related]
20. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines. Yoshida M; Khokhar AR; Siddik ZH Cancer Res; 1994 Jul; 54(13):3468-73. PubMed ID: 8012968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]